Multiple Sclerosis (MS) clinical trials
196 active trials name this condition (recorded in the registry as “Multiple Sclerosis”) . Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
- Gait Adaptation Study
- Dry Needling in Multiple Sclerosis
- Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis
- A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
- Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)
- Functional Balance Intervention in Multiple Sclerosis
- Non-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis
- Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
- Increasing Physical Activity for Adults With Multiple Sclerosis (MS)
- A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis
- Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection
- Testing the Feasibility of Computer-based Cognitive Training in Individuals with Multiple Sclerosis Living in the Community
- Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
- Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
- Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
- A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
- Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
- Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
- Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
- High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis
- Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
- Home Based Functional Balance Intervention for Multiple Sclerosis
- Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue
- Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
- An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
- Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
- Effects of Torso Weighting on Muscle Activation During Balance Tests in Individuals With and Without Multiple Sclerosis
- Dry Needling in Multiple Sclerosis
- The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
- Effects of Ublituximab on Motor Functions in Multiple Sclerosis
- Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis
- A Study of the MIND Diet for Persons With Multiple Sclerosis
- Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
- A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
- Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS
- A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
- Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients
- Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
- Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
- Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With Hypertension
- Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Multiple Sclerosis” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.